Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26076726 | 1.00 | PTGER4 (0.34) | PTGER4CXCR3POLBPDE5AFSCN1 | |
| SCHEMBL10347552 | 1.00 | PTGER4 (0.34) | PTGER4CXCR3POLBPDE5AFSCN1 | |
| SCHEMBL26076711 | 0.92 | PTGER4 (0.34) | PTGER4CXCR3POLBFSCN1HTR2A | |
| SCHEMBL3985755 | 0.92 | PTGER4 (0.34) | PTGER4CXCR3POLBPDE5AFSCN1 | |
| SCHEMBL3985769 | 0.88 | GRM2 (0.35) | PTGER4PDE5AHTR2AGRM2KCNJ6 | |
| SCHEMBL3987455 | 0.87 | GRM2 (0.34) | PTGER4HTR2AGRM2KCNJ6KCNJ5 | |
| SCHEMBL13846608 | 0.87 | GRM2 (0.34) | PTGER4HTR2AGRM2KCNJ6KCNJ5 | |
| SCHEMBL3991472 | 0.84 | AR (0.32) | PTGER4HTR2AGRM2KCNJ6KCNJ5 | |
| SCHEMBL4748777 | 0.84 | FSCN1 (0.41) | FSCN1HTR2AGRM2 | |
| SCHEMBL14051992 | 0.84 | FSCN1 (0.41) | FSCN1HTR2AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260069698-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | UNIV NEBRASKA (US) | 2026-03-12 | — | — | US | claimed |
| US-20250255968-A1 | INTRAVAGINAL DEVICES FOR DRUG DELIVERY | KISER PATRICK F (US) | 2025-08-14 | — | — | US | claimed |
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| WO-2024263781-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-26 | — | — | WO | claimed |
| CN-118873676-A | Antiviral prodrugs and nano-formulations thereof | 内布拉斯加大学董事会 | 2024-11-01 | — | — | CN | claimed |
| US-20240342106-A1 | NANOPARTICLES AND USES THEREOF FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | UNIV MIAMI (US) | 2024-10-17 | — | — | US | claimed |
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | PARDES BIOSCIENCES INC (US) | 2024-08-22 | — | — | US | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| US-20220380341-A1 | INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-12-01 | — | — | US | claimed |
| WO-2022221686-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2022-10-20 | — | — | WO | claimed |
| US-20220211716-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-07-07 | — | — | US | claimed |
| US-20220175936-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-06-09 | — | — | US | claimed |
| CN-107614515-B | T20 construct for anti-HIV (human immunodeficiency Virus) therapy and/or vaccine | 免疫医疗公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| US-10596103-B2 | Drug delivery system for delivery of anti-virals | Merek Sharp & Dohme B.V. (NL) | 2020-03-24 | — | — | US | claimed |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20160296467-A1 | DRUG DELIVERY SYSTEM FOR DELIVERY OF ANTI-VIRALS | MERCK SHARP & DOHME B.V. (NL) | 2016-10-13 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | PTGER4 1772/4885CXCR3 60/4885POLB 34/4885 |
| US-20220380341-A1 | INHIBITORS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | NAT1, CXCR4, HAX1 | PTGER4 3068/4885CXCR3 82/4885POLB 2689/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | PTGER4 1772/4885CXCR3 60/4885POLB 34/4885 |
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CPN1, CTSL | PTGER4 3392/4885CXCR3 2833/4885POLB 2783/4885 |
| US-20220211716-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | TYMP, PNP, SLC29A1 | PTGER4 2211/4885CXCR3 1685/4885POLB 984/4885 |
| US-20220175936-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | TYMP, PNP, SLC29A1 | PTGER4 2211/4885CXCR3 1685/4885POLB 984/4885 |
| US-20240342106-A1 | NANOPARTICLES AND USES THEREOF FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CD47, HAVCR2, TSG101 | PTGER4 4845/4885CXCR3 642/4885POLB 2056/4885 |
| US-20160296467-A1 | DRUG DELIVERY SYSTEM FOR DELIVERY OF ANTI-VIRALS | AHSA1, VARS1, VMA21 | PTGER4 1869/4885CXCR3 4854/4885POLB 1090/4885 |
| US-10596103-B2 | Drug delivery system for delivery of anti-virals | AHSA1, VARS1, VMA21 | PTGER4 1869/4885CXCR3 4854/4885POLB 1090/4885 |
| US-20260069698-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | MAP2K6, MAP2K7, CDK8 | PTGER4 1717/4885CXCR3 2437/4885POLB 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.